WOCKPHARMA

filed a New Drug Application with the US FDA for Zaynich, a novel antibiotic targeting multi-drug resistant gram-negative bacteria, causing complicated urinary tract infections. The drug has shown a 96.8% cure rate in clinical trials and could reach US markets in FY27, with a potential $7 billion global market worth.